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Clinical characteristics and outcomes of acute coronary syndrome 
patients with intra-aortic balloon pump inserted in intensive
cardiac care unit of a tertiary clinic
Tersiyer bir kliniğin ileri kardiyak bakım ünitesinde intra-aortik balon pompası
takılan akut koroner sendromlu hastaların klinik özellikleri ve sonlanımları
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Objective: An intra-aortic balloon pump (IABP) is a mechan-
ical support device that is used in addition to pharmacologi-
cal treatment of the failing heart in intensive cardiac care unit 
(ICCU) patients. In the literature, there are limited data re-
garding the clinical characteristics and in-hospital outcomes 
of acute coronary syndrome patients in Turkey who had an 
IABP inserted during their ICCU stay. This study is an analy-
sis of the clinical characteristics and outcomes of these acute 
coronary syndrome patients.
Methods: The data of patients who were admitted to the 
ICCU between September 2014 and March 2017 were ana-
lyzed retrospectively. The data were retrieved from the ICCU 
electronic database of the clinic. A total of 142 patients treated 
with IABP were evaluated in the study. All of the patients were 
in cardiogenic shock following percutaneous coronary inter-
vention, at the time of IABP insertion.
Results: The mean age of the patients was 63.0±9.7 years 
and 66.2% were male. In-hospital mortality rate of the study 
population was 54.9%. The patients were divided into 2 groups, 
consisting of survivors and non-survivors of their hospitaliza-
tion period. Multivariate analysis after adjustment for the pa-
rameters in univariate analysis revealed that ejection fraction, 
Thrombolysis in Myocardial Infarction flow score of ≤2 after the 
intervention, chronic renal failure, and serum lactate and glu-
cose levels were independent predictors of in-hospital mortality.
Conclusion: The mortality rate remains high despite IABP 
support in patients with acute coronary syndrome. Patients 
who are identified as having a greater risk of mortality accord-
ing to admission parameters should be further treated with 
other mechanical circulatory support devices.
Amaç: İntraaortik balon pompasının (İABP) kardiyak yoğun 
bakım ünitesi (KYBÜ) hastalarındaki kalp pompa yetersizli-
ğinde farmakolojik tedaviye ek destek tedavisi olarak kulla-
nılması kabul görmüş bir uygulamadır. Kardiyak yoğun bakım 
ünitesine  kabul edilen İABP takılmış akut koroner sendromlu 
hastaların klinik özellikleri ve hastane içi sonuçları hakkında 
literatürde ülkemiz hakkında sınırlı veri vardır. Çalışmamızda 
bu akut koroner sendromlu hastaların klinik özelliklerini ve so-
nuçlarını incelemeyi amaçladık.
Yöntemler: Eylül 2014 ile Mart 2017 arasında KYBÜ’ye kabul 
edilen hastaların verileri geriye dönük olarak incelendi. Veriler 
kliniğimizin KYBÜ elektronik veri tabanından elde edildi. İntra-
aortik balon pompası takılan 142 hasta çalışmamızda değer-
lendirildi. Perkütan koroner girişimi takiben, tüm hastalar İABP 
takılması sırasında kardiyojenik şoktaydı.
Bulgular: Hastaların ortalama yaşı 63.0±9.7 idi ve %66.2’si 
erkekti. Çalışma grubunun hastane içi mortalitesi %54.9 idi. 
Hastalar hastanedeki içi mortalitelerine göre hayatta kalanlar 
ve hayatını kaybedenler olmak üzere ikiye ayrıldı. Tek değiş-
kenli analizdeki parametrelerin kullanımı ile yapılan çok de-
ğişkenli analizde ejeksiyon fraksiyonu, perkütan girişim sonra-
sında TIMI ≤2 akım olması, kronik böbrek yetersizliği, serum 
laktat ve glukoz düzeyleri hastane içi mortalitenin bağımsız 
öngördürücüleri olarak saptandı.
Sonuç: Akut koroner sendromlu hastalarda İABP desteğine 
rağmen mortalite yüksektir. Başvuru parametrelerine göre 
mortalite bakımından yüksek riskli olarak belirlenmiş hastalar 
diğer mekanik destek cihazları ile tedavi edilmelidir.
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The well-ac-cepted clin-
ical indications 
for IABP admin-
istration are car-
diogenic shock 
before or after 
coronary revascu-
larization, high-
risk percutaneous 
revascularization, 
mechanical com-
plications of my-
ocardial infarction 
(MI), postopera-
tive pump failure, 
refractory angina, 
bridge to cardiac transplantation, and refractory ar-
rhythmias. There are 2 main targets for IABP: to sup-
port hemodynamics in cardiogenic shock, and to treat 
refractory ischemia in patients with coronary artery 
disease.
IABP use in acute MI has undergone serious change 
after observational and randomized, controlled, clin-
ical trials. In the beginning, the 2008 European and 
2009 American guidelines recommended IABP use as 
class IC and IB, respectively, in acute MI complicated 
with cardiogenic shock.[1,2] Yet, despite solid recom-
mendations in the guidelines, IABP was underused 
in routine clinical practice, with a 25% to 40% rate 
worldwide.[3] The underlying reason for this is consid-
ered to be secondary to challenging studies.[4,5] No 30-
day mortality benefit was observed between patients 
with and without IABP in the Intra-aortic Balloon 
Pump in Cardiogenic Shock (IABP-SHOCK) trial.[6] 
IABP use in MI complicated with cardiogenic shock 
regressed further in recent guidelines; the 2013 Amer-
ican guidelines recommended it as class IIA, whereas 
the 2014 European guidelines moved it to class III.[7,8]
IABP is also recommended as mechanical circula-
tory support in heart failure patients while bridging to 
transplantation. Even though a left ventricular assist 
device (LVAD) is widely recommended under the title 
of “mechanical circulatory support,” temporary per-
cutaneous support devices such as IABP may serve 
as a bridge to definite therapy in selected patients, ac-
cording to the 2016 European Society of Cardiology 
heart failure guidelines.[9] The recommendation for 
IABP appears in Interagency Registry for Mechani-
cally Assisted Circulatory Support (INTERMACS) 
level 1 heart failure patients (crush and burn state), 
whereas LVAD dominates the guideline by standing 
in all other INTERMACS levels of patients with ad-
vanced heart failure.[10]
In our country, unfortunately, there are limited data 
on IABP use in acute coronary syndrome patients. 
The aim of this study was to evaluate the clinical char-
acteristics and predictors of mortality of 142 patients 
with an IABP inserted in the intensive cardiac care 
unit (ICCU) of a tertiary clinic.
METHODS
Study design and patient population
This study was designed as a retrospective, observa-
tional, single-center study. The data of patients who 
were admitted to the ICCU between September 2014 
and March 2017 were analyzed. A total of 142 acute 
coronary syndrome patients treated with an IABP 
(1.78%) were assessed. All of the patients were evalu-
ated using demographic parameters, routine biochem-
istry, complete blood count, electrocardiography, 
transthoracic echocardiography (TTE), and coronary 
angiography. In all, 22 patients were excluded from 
the study because the IABP insertion time and rea-
son did not meet the study criteria: 5 patients had the 
IABP inserted before the percutaneous coronary inter-
vention (PCI), and 17 congestive heart failure (CHF) 
patients had the IABP inserted for other reasons dur-
ing their hospitalization. The study was approved by 
the local medical ethics committee.
A clinical history of risk factors, such as age, sex, 
hypertension (HT), diabetes mellitus (DM), smoking, 
hyperlipidemia, peripheral artery disease, or chronic 
lung and kidney disease was determined from the 
ICCU electronic database. Echocardiographic find-
ings were also obtained from the same database. TTE 
was performed using a Vivid 3 system (GE Vingmed 
Ultrasound AS, Horten, Norway) in the first 48 hours 
in the coronary care unit and left ventricular ejection 
fraction (EF) was calculated using Simpson method.
[11] The pulmonary arterial peak systolic pressure was 
calculated using the simplified Bernoulli equation.
Blood values obtained from venous blood samples 
at hospital admission were recorded from the medical 
reports. White blood cell count (WBC), hemoglobin 
Abbreviations:
CHF Congestive heart failure
CI	 Confidence	interval
CRF	 Chronic	renal	failure
DM Diabetes mellitus
EF	 Ejection	fraction
HT Hypertension
IABP	 Intra-aortic	balloon	pump
ICCU	 Intensive	cardiac	care	unit
INTERMACS	 Interagency	Registry	for
	 Mechanically	Assisted
	 Circulatory	Support
LVAD	 Left	ventricular	assist	device
MI	 Myocardial	infarction
OR	 Odds	ratio
PCI	 Percutaneous	coronary
 intervention
TIMI		 Thrombolysis	in	Myocardial
	 Infarction
TTE	 Transthoracic	echocardiography
WBC	 White	blood	cell
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level, and neutrophil count were measured as part of 
the automated complete blood count using a Coulter 
LH 780 Hematology Analyzer (Beckman Coulter, 
Inc., Brea, CA, USA). Biochemical measurements 
were performed using Siemens Healthcare Diagnostic 
Products GmbH kits and calibrators (Marburg, Ger-
many). 
The IABP was inserted via the femoral artery with-
out a sheath insertion. The IABP was instituted using 
1:1 electrocardiographic triggering and weaning was 
performed by reduction of the electrocardiographic 
triggering from 1:1 to 1:2 to 1:3 trigger ratios. The 
IABP was inserted in all of the patients after PCI, and 
the decision to use an IABP was left to the discretion 
and guidance of the supervising cardiologist. 
Definitions
HT was defined as systolic pressure ≥140 mmHg, di-
astolic pressure ≥90 mmHg, or a history of antihy-
pertensive medication use. DM was defined as use of 
insulin or antidiabetic agents in the patient’s medical 
history, or a fasting glucose level ≥126 mg/dL. Hyper-
lipidemia was defined as a serum total cholesterol 
≥240 mg/dL, serum triglyceride ≥200 mg/dL, low-
density lipoprotein cholesterol ≥130 mg/dL, or pre-
viously diagnosed hyperlipidemia. Cardiogenic shock 
was defined as hypotension (systolic blood pressure 
<90 mmHg) despite adequate filling status with signs 
of hypoperfusion despite vasopressor treatment with 
at least 2 vasopressors.
Statistical analysis
The data analysis was performed using IBM SPSS 
Statistics for Windows, Version 20.0 (IBM Corp., 
Armonk, NY, USA) software. The Kolmogorov-
Smirnov test was used to test the distribution pattern. 
Data were presented as mean±SD for normally dis-
tributed data, and as median (interquartile range) for 
continuous variables that were not normally distrib-
uted. The number of cases and percentages were used 
for categorical data. The mean differences between 
groups were compared using the Student’s t-test. The 
Mann-Whitney U test was applied for comparisons of 
the data that were not normally distributed. Categori-
cal data were analyzed with Fisher’s exact test when 1 
or more cells had an expected frequency of 5 or less. 
Otherwise, Pearson’s chi-square test was applied. 
Multiple logistic regression analysis using the back-
ward logistical regression method was applied to de-
termine the best predictor(s) that affect mortality after 
adjustment for all possible confounding factors. Any 
variable that had a univariable test p value <0.25 was 
accepted as a candidate for a multivariable model, 
along with all variables of known clinical importance. 
Odds ratios (ORs) and 95% confidence intervals (CIs) 
for each independent variable were also calculated. 
A p value less than 0.05 was considered statistically 
significant.
RESULTS
A total of 142 (66.2% male) acute coronary syndrome 
patients who had an IABP inserted in the ICCU were 
evaluated in this study. The patients were analyzed 
with respect to in-hospital mortality (Table 1). The 
mean age of the patients was 63.0±9.7 years. Among 
these patients, 67 had HT (47.1%), 73 had DM 
(51.4%), and 87 (61.3%) were smokers. In addition, 
54 of the patients had previously been diagnosed with 
hyperlipidemia (38.0%). Furthermore, 27 patients 
(19.0%) had MI, 7 patients had a cerebrovascular 
accident (4.9%), 1 patient had aortic valve replace-
ment (1.2%), 19 patients had coronary artery bypass 
graft surgery (13.3%), and 30 patients had PCI history 
(21.1%). In the group, 60 patients (42.2%) had a CHF 
diagnosis, 17 had (11.9%) chronic obstructive pul-
monary disease, and 55 patients (38.7%) had chronic 
renal failure (CRF). 
All of the patients were under inotropic agent treat-
ment when the IABP was inserted. The patients were 
all treated with primary PCI before the IABP inser-
tion. Survivors were notably younger than non-sur-
vivors (p<0.001). The prevalence of CRF was found 
to be significantly greater in non-survivors (p<0.001). 
A TIMI flow score ≤2 in a culprit artery after the in-
tervention was also found to be significantly greater 
in non-survivors (p<0.001). The left ventricle EF was 
significantly greater in survivors (p=0.012). 
Laboratory data of the study groups are provided 
in Table 2. The serum creatinine, glucose, and lactate 
levels were notably higher in non-survivors (p<0.001, 
p=0.016, and p<0.001, respectively). The univariate 
and multivariate logistic regression predictors of in-
hospital mortality are indicated in Table 3 and Table 
4. CRF (OR: 2.855; 95% CI: 1.088–7.493; p=0.033), 
TIMI score post PCI ≤2 (OR: 8.163; 95% CI: 2.599–
25.634; p<0.001), glucose (OR: 1.014; 95% CI: 
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Table 1. Comparison of demographic and clinical characteristics of patients according to mortality
  Mortality (–) Mortality (+) p
  (n=64) (n=78)
Age (years) 58.0 (52.0–67.5) 66.0 (58.0–72.0) <0.001
Female/Male 19 (29.7%)/ 45 (70.3%) 29 (37.2%)/49 (62.8%) 0.348
Hypertension 31 (48.4%) 36 (46.2%) 0.786
Diabetes mellitus 32 (50.0%) 41 (52.6%) 0.761
Smoking 39 (60.9%) 48 (61.5%) 0.942
Hyperlipidemia 23 (35.9%) 31 (39.7%) 0.642
Previous myocardial infarction 16 (25.0%) 11 (14.1%) 0.100
Previous cerebrovascular accident 2 (3.1%) 5 (6.4%) 0.458
Previous aortic valve replacement 0 1 (1.3%) 1.000
Previous coronary artery bypass graft 9 (14.1%) 10 (12.8%) 0.829
Previous percutaneous coronary intervention 13 (20.3%) 17 (21.8%) 0.830
Congestive heart failure 4 (6.2%) 10 (12.8%) 0.191
Chronic obstructive pulmonary disease 9 (14.1%) 8 (10.3%) 0.487
Chronic renal failure 16 (25.0%) 44 (56.4%) <0.001
Peripheral arterial disease 4 (6.2%) 7 (9.0%) 0.754
Anterior wall myocardial infarction 36 (56.2%) 43 (55.1%) 0.893
Atrial fibrillation 3 (4.7%) 4 (5.1%) 1.000
TIMI flow in culprit before intervention
 TIMI  0 57 (89.1%) 73 (93.6%) 0.335
 TIMI  1 7 (10.9%) 5 (6.4%) 0.335
TIMI flow in culprit after intervention
 TIMI ≤2 8 (12.5%) 45 (57.7%) <0.001
 TIMI 3 56 (87.5%) 33 (42.3%) <0.001
Coronary artery bypass graft 11 (17.2%) 11 (14.1%) 0.613
Intervened vessel
 Left anterior descending artery 35 (54.7%) 45 (57.7%) 0.719
 Circumflex artery 6  (9.4%) 3 (3.8%) 0.299
 RCA: Right coronary artery 11 (17.2%) 10 (12.8%) 0.466
 Multivessel 11 (17.2%) 20 (25.6%) 0.225
IABP usage days 3.0 (2.0–4.0) 3.0 (1.0–5.0) 0.661
Inotropic agents
 Dobutamine infusion 35 (54.7%) 37 (47.4%) 0.390
 Dopamine infusion 59 (92.2%) 74 (94.9%) 0.731
 Noradrenaline infusion 48 (75.0%) 57 (73.1%) 0.795
 Adrenaline infusion 13 (20.3%) 21 (26.9%) 0.358
Central venous pressure 9.0 (6.0–11.5) 9.0 (8.0– 12.0) 0.288
Left ventricular ejection fraction (%) 35.0 (30.0–40.0) 26.5 (20.0–35.0) 0.012
Left ventricular end-diastolic diameter (cm) 5.40 (4.95–5.60) 5.60 (5.10–6.20) 0.060
Left ventricular end-systolic diameter (cm) 4.00 (3.30–4.80) 4.50 (3.90–5.00) 0.003
Tricuspid annular plane systolic excursion (cm) 1.85 (1.55–2.15) 1.80 (1.50–2.20) 0.637
Pulmonary artery systolic pressure (mmHg) 25.0 (20.0–35.0) 30.0 (24.0–38.0) 0.049
Mitral regurgitation ≥+3 7 (10.9%) 17 (21.8%) 0.086
Intra-aortic balloon pump related complications
 Bleeding 12 (18.8%) 16 (20.5%) 0.793
 Vascular injury 1 (1.6%) 3 (3.8%) 0.627
 Thrombocytopenia 6 (9.4%) 8 (10.3%) 0.861
Continuous variables are presented as mean±standard deviation. Nominal variables are presented as frequency (%). TIMI: Thrombosis in Myocardial Infarction.
1.001–1.027; p=0.035), lactate (OR: 1.468; 95% CI: 
1.191–1.809; p<0.001), and EF (OR: 0.927; 95% CI: 
0.882–0.975; p=0.003) were defined as multivariate 
predictors of in-hospital mortality. 
DISCUSSION
The main findings of our study were as follows: suc-
cessful PCI is one of the important determinants of 
survival in patients with an IABP, and EF, CRF, and 
admission glucose and lactate levels are independent 
predictors of mortality in patients with an IABP.
An IABP is still one of the most-used methods for 
mechanical hemodynamic support in the ICCU, al-
though its benefit continues to be debated. It is mostly 
inserted in patients with MI complicated with car-
diogenic shock in addition to conventional medical 
therapy. Despite mechanical support, the mortality 
rate of hemodynamically deteriorated patients is still 
unacceptably high. The in-hospital mortality rate of 
patients treated with an IABP varies according to the 
clinical indication for IABP use. The in-hospital mor-
tality rate for patients treated with an IABP in Taiwan 
was recently reported to be 13.8%.[12] It was higher 
in the United States (20.1%) and Europe (28.7%) be-
tween 1997 and 2002.[13] Our mortality ratio was quite 
high, 54.9%, which was considered to be the result 
of strictly selected, critically ill patients. An IABP is 
most often used in patients with coronary artery dis-
ease.[12,14] The in-hospital mortality rate of patients 
with acute MI complicated by cardiogenic shock was 
reported as 47.9% by Babaev et al.,[15] and as 42% in 
the Benchmark Counterpulsation Outcomes Registry 
database.[16] When compared with other studies, the 
higher mortality rate in our study might be explained 
by the inclusion of a larger percentage of Killip class 
IV acute MI patients who were treated with PCI. 
In the literature, there are limited data regarding 
the parameters that effect mortality in patients with an 
IABP. Therefore, we sought to compare survivors and 
Table 2. Comparison of laboratory parameters of patients according to mortality
  Mortality (–)  Mortality (+)  p
  (n=64) (n=78)
Laboratory variables at admission
 Hematocrit (%) 36.5±6.0 36.7±6.4 0.868
 Hemoglobin (g/dL) 12.3±2.0 12.3±2.1 0.837
 White blood cell (cells/µL) 17.3 (13.7–19.3) 17.5 (12.6–23.2) 0.396
 Platelet count (/mm3) 255 (202–265) 243 (199–291) 0.870
 Creatinine (mg/dL) 1.10 (0.86–1.23) 1.59 (1.22–1.95) <0.001
 Blood urea nitrogen (mg/dL) 22.0 (16.0–27.0) 25.5 (18.0–40.0) 0.016
 Potassium (mEq/L) 4.15 (3.50–4.50) 4.80 (4.00–5.50) 0.176
 Sodium (mEq/L) 136 (134–139) 138 (131–143) 0.380
 Aspartate transaminase 221 (51–283) 333 (41–342) 0.034
 Alanine transaminase 54 (32–77) 53 (27–135) 0.170
 Lactate dehydrogenase 394 (247–929) 641 (389–951) 0.042
 International normalized ratio  1.3 (1.1–1.6) 1.4 (1.2–1.9) 0.198
 Glucose (mg/dL) 120 (95–135) 136 (93–167) 0.016
 C-reactive protein 3.70 (2.75–4.50) 3.80 (3.50–4.50) 0.107
 Lactate 2.95 (2.25–4.40) 5.50 (4.20–9.40) <0.001
Peak values
 Creatinine 1.34 (1.11–2.05) 3.05 (1.91–4.10) <0.001
 Aspartate transaminase 187 (70–442) 475 (166–1475) 0.001
 Alanine transaminase 89 (59–155) 142 (98–916) 0.012
 Lactate dehydrogenase 905 (583–1479) 1325 (691–1973) 0.076
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ter intervention was also demonstrated to be a strong 
predictor of death by De Felice et al.[19] According 
to the findings of our study, TIMI flow score may be 
used as a risk stratification of patients with an IABP. 
In addition, the admission serum glucose and lactate 
levels appeared in a new score designed using a step-
wise, multivariable regression analysis for patients 
with cardiogenic shock.[20] EF has been universally 
accepted as a cardiac parameter with proven predic-
tive value.[21]
In our study, bleeding, vascular injury, and throm-
bocytopenia were the complications related to IABP 
insertion. They are frequently encountered compli-
cations of IABP. Infections, balloon rupture, balloon 
non-survivors in order to determine predictive param-
eters. Between the 2 groups, TIMI score post-PCI of 
≤2, EF, CRF, and admission glucose and lactate levels 
were demonstrated to be statistically higher in non-
survivors. Additionally, EF was found to be notably 
higher in the survivor group. CRF is a well-accepted 
risk factor for mortality in high-risk patients. CRF 
was detected as a predictor of in-hospital mortality in 
patients with acute heart failure.[17] Baseline impaired 
renal function was associated with poor prognosis in 
patients with ST-elevation MI and cardiogenic shock.
[18] Similarly, CRF was revealed to be an independent 
mortality predictor in patients with an IABP in our 
study. A TIMI flow score of ≤2 in the culprit artery af-
Table 3. Univariate logistic regression analyses between in-hospital mortality and baseline, clinical, angiographic 
and laboratory data 
Univariate analysis p OR (95% CI)
Age <0.001 1.079 (1.038–1.122)
Chronic renal failure <0.001 3.882 (1.887–7.987)
Previous congestive heart failure 0.200 2.206 (0.658–7.400)
Thrombosis in myocardial infarction ≤2 after intervention <0.001 9.545 (4.014–22.701)
Blood urea nitrogen 0.007 1.031 (1.008–1.054)
Aspartate transaminase 0.188 1.000 (1.000–1.001)
Potassium  0.177 1.491 (0.835–2.660)
C-reactive protein 0.077 1.318 (0.970–1.791)
Glucose 0.009 1.012 (1.003–1.021)
Lactate <0.001 1.562 (1.290–1.891)
Ejection fraction  <0.001 0.962 (0.931–0.995)
Left ventricular end-diastolic diameter 0.054 1.608 (0.958–2.700)
Left ventricular end-systolic diameter 0.022 1.837 (1.211–2.787)
Pulmonary artery systolic pressure 0.200 1.021 (0.989–1.053)
Mitral regurgitation ≥+3 0.091 2.269 (0.876–5.876)
Multivessel intervention 0.228 1.661 (0.728–3.790)
OR: Odds ratio; CI: Confidence interval.
Table 4. Multivariate analysis demonstrating independent predictors of mortality
Multivariate analysis p OR (95% CI)
Chronic renal failure 0.033 2.855 (1.088–7.493)
Glucose level 0.035 1.014 (1.001–1.027)
Lactate level <0.001 1.468 (1.191–1.809)
Thrombosis in myocardial infarction ≤2 after intervention <0.001 8.163 (2.599–25.634)
Ejection fraction 0.003 0.927 (0.882–0.975)
OR: Odds ratio; CI: Confidence interval.
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hemodynamic support with Impella 2.5 versus intra-aortic 
balloon pump in patients undergoing high-risk percutaneous 
coronary intervention: the PROTECT II study. Circulation 
2012;126:1717–27. [CrossRef]
10. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Steven-
son LW, Blume ED, et al. Sixth INTERMACS annual re-
port: a 10,000-patient database. J Heart Lung Transplant 
2014;33:555–64. [CrossRef]
11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux 
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of the left ventricle by two-dimensional echocardiography. 
entrapment, and cell destruction are other reported 
complications. Despite the fact that the encountered 
complications were similar to those described in the 
literature, major complications were not seen in our 
study population.[22] The risk for complications poten-
tially increases with longer duration of IABP use.[22] 
No major complication in our study was thought to be 
secondary to shorter duration of IABP use. 
Study limitations
One of the limitations of our study is its retrospective 
observational design. We had a limited number of pa-
tients with an IABP inserted, which prevents the gen-
eralizability of our findings. Mortality was found to 
be extremely high due to the inclusion of Killip class 
IV acute MI patients treated with PCI.
Conclusion
Our study revealed that an IABP is a poor choice in 
patients with cardiogenic shock due to acute coronary 
syndrome and that the mortality rate in these patients 
was unexpectedly higher than the rates reported in the 
literature. Renal, echocardiographic, and angiographic 
parameters can be used as mortality predictors in pa-
tients with an IABP. As a result, insertion of an IABP 
is a choice available to provide mechanical support in 
selected patients that should be made based on correct 
timing and clinical indication. Patients who have a 
higher risk of mortality should be further treated with 
other mechanical circulatory support devices.
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